Get the Stockscreener App
1.02
0.00%
0.00
After Hours:
1.01
-0.01
-0.98%
Allarity Therapeutics Inc stock is traded at $1.02, with a volume of 310.25K.
It is up +0.00% in the last 24 hours and up +3.03% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
310.25K
Relative Volume:
0.52
Market Cap:
$15.38M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00495
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
+2.35%
1M Performance:
+3.03%
6M Performance:
-25.00%
1Y Performance:
+426.04%
1-Day Range:
$0.9894
$1.03
1-Week Range:
$0.945
$1.14
52-Week Range:
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.02 | 15.38M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Is Allarity Therapeutics Inc. a good long term investmentBreakthrough financial growth - PrintWeekIndia
What drives Allarity Therapeutics Inc. stock priceLightning-fast growth - PrintWeekIndia
Allarity Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Query - Autocar Professional
How Allarity Therapeutics Inc. stock performs during market volatilityFree Stock Trading Community - Newser
What analysts say about Allarity Therapeutics Inc. stockTremendous return rates - Autocar Professional
Will Allarity Therapeutics Inc. stock benefit from interest rate changesFree Stock Investment Growth Plan - beatles.ru
Does Allarity Therapeutics Inc. stock pay reliable dividendsRisk Adjusted Stock Signals - Newser
Allarity Therapeutics Secures New EU Commercial Agreement - TipRanks
Why Allarity Therapeutics Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
What makes Allarity Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser
Allarity Therapeutics Announces New Licensing and - GlobeNewswire
Allarity Therapeutics Signs New Precision Oncology Licensing Deal for Breast Cancer | ALLR Stock News - Stock Titan
Allarity Therapeutics appoints Jeff Ervin as CFO - MSN
Jeffrey S. Ervin Appointed as Allarity’s New CFO - The Globe and Mail
Allarity Therapeutics appoints Jeff Ervin as new CFO By Investing.com - Investing.com Nigeria
Allarity Therapeutics, Inc. Announces Chief Financial Officer Changes - MarketScreener
Allarity Therapeutics appoints Jeffrey S. Ervin as part-time chief financial officer - Investing.com Nigeria
Allarity Therapeutics appoints Jeff Ervin as new CFO - Investing.com
Allarity Therapeutics Appoints Jeff Ervin To Succeed Alexander Epshinsky As CFO - Nasdaq
Allarity Therapeutics Appoints Jeff Ervin as New Chief Financial Officer - Nasdaq
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - GlobeNewswire
Former NYSE Executive Takes CFO Role at Cancer Drug Developer Allarity Therapeutics - Stock Titan
Allarity Therapeutics Secures Australian Patent for DRP® Platform - The Globe and Mail
Allarity Therapeutics Advances Phase 2 Stenoparib Trial - TipRanks
Allarity Therapeutics receives patent acceptance in Australia for cancer diagnostic - Investing.com
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic - The Manila Times
Allarity Therapeutics Doses Second Patient in Phase 2 Ovarian Cancer Trial - MarketScreener
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):